9 March 2022
Proveca announces new partnership with ExCEEd Orphan
Proveca has announced its new partnership with ExCEEd Orphan to commercialise and distribute Sialanar® exclusively in Central and Eastern Europe (CEE). Under the terms of the agreement, ExCEEd Orphan will have exclusive rights to seek reimbursement, distribute and market...
28 February 2022
Gendius initiates GP data study to develop enhanced risk prediction tools for diabetes
UK medtech start-up Gendius has partnered with over 60 primary care practices on a data extraction study to develop enhanced risk prediction tools for people with diabetes. The study will analyse real-world data from thousands of people with diabetes in order to validate and...
7 February 2022
QV Bioelectronics Awarded £630,000 Under Innovate UK Biomedical Catalyst Award
• Funding will accelerate development of the GRACE implant to treat brain tumour patients with electric field therapy. • The project will accelerate the collection of preclinical safety and efficacy data, providing preclinical proof of concept whilst forming part of regulatory...
21 January 2022
Two new senior appointments at Manchester Imaging
Drs Ben Atkins and Jana Denzel join AI provider Manchester Imaging … Manchester Imaging Limited (MIL) the company behind AssistDent®, has announced two new appointments to its team of dental technology specialists, Drs Ben Atkins and Jana Denzel. A spokesperson explained:
7 January 2022
Alder Hey children’s hospital and Proveca announce collaboration
Alder Hey children’s hospital and Proveca Ltd are joining forces with the aim of improving medicines for children and young people. The new collaborative partnership plans to provide the best pharmaceutical treatments for children by identifying existing gaps and...
15 December 2021
Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
Lipid reformulation of anti-inflammatory compound MT1980 for POCD accelerating into clinic in 2022 … Manchester, UK, Dec 14, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised an additional £0.5 million to accelerate the development...
14 December 2021
INFEX Therapeutics agrees partnership with Colibri Scientific to provide services for RESP-X program
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Colibri Scientific, to provide logistics and sample operational services for Infex’s RESP-X program. RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is...
13 December 2021
Panthera Biopartners leads the way in the UK with specialist research sites for NASH and NAFLD studies
With access to leading hepatologists, biopsy theatres, fibroscans at specialist sites and ongoing mass screening programmes Panthera can help pharma and CROs find a treatment for this increasingly common, progressive, and life-threatening diseases. Non-Alcoholic steatohepatitis...
2 December 2021
INFEX Therapeutics scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat COVID-19 and new variants of the disease, such as the Omicron variant. Infex Therapeutics’ COV-X...
23 November 2021
Proveca sponsored clinical trial starts in France to evaluate the impact of its drug Sialanar®
The SALIVA (Sialanar® plus orAl rehabiLitation against placebo plus oral rehabilitation for chIldren and adolescents with seVere sialorrhoeA and neurodisabilities) study … In May 2021, the first child was enrolled into the SALIVA study, a trial sponsored by Proveca Pharma...